Prostate Specific Antigen (PSA)
Abiraterone acetate and prednisone reduced PSA levels in a small group of clinical trial participants with metastatic prostate cancer who did not initially respond to ADT.
Conversations about benefits and drawbacks of PSA testing improved after the USPSTF updated its recommendations on PSA testing; however, some disparities in quality of these discussions increased.
Following the USPSTF recommendation against routine PSA testing in all men, incidence rates of early stage prostate cancer in men 50 years and older declined substantially, according to a recent study.
Screening PSA levels at midlife could identify men who are at greater risk of developing prostate cancer later in life and who should be monitored more closely.
PSA levels in midlife strongly predict future lethal prostate cancer risk in U.S. cohort.
New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.
A new urine assay that can detect genetic changes correlated with prostate cancer correctly identified cancer grade in 92% of men with elevated PSA levels and high-grade cancers.
Among persons 65 years or older with limited life expectancies of less than 10 years, an estimated 15.7% may have undergone nonrecommended screenings for prostate and breast cancers.
Important discussions about prostate cancer screening and treatment are not occurring between men and their health care team.
African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.
Repeating PSA Test in Select Patients Can Mitigate Controversial Issues in Prostate Cancer ScreeningDecember 29, 2015
Some task forces advocate abandoning the use of the screening PSA test because it leads to unnecessary prostate biopsies. Canadian researchers show that repeating the test in select patients can reduce the number of biopsies.
The impact on PSA screening and prostate cancer incidence before and after the 2012 USPSTF screening recommendations were examined in two recent studies.
A new test is better at detecting aggressive prostate cancer than measuring PSA levels. The new test discovers aggressive cancer earlier and reduces the number of false positive tests and unnecessary biopsies.
Using watchful waiting or active surveillance to monitor men with very low- and low-risk prostate cancer is effective in many patients with localized tumors and could prevent aggressive and unnecessary treatments.
Novel test combines two markers with prostate-specific antigen (PSA) for improved prostate cancer detectionJune 08, 2015
A new test that employs urine analysis demonstrated improved prostate cancer detection over traditional models based on prostate-specific antigen (PSA) levels.
An inexpensive, quick-result test has been shown in recently published studies to be more sensitive and more exacting than the current standard test for early stage prostate cancer.
A retrospective analysis of patient data found the proportion of men with diagnoses of intermediate- and high-risk prostate cancer increased by nearly 6% between 2011 and 2013.
Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy are advised to receive more aggressive radiation therapy treatment, according to a study.
Study examines vaccine therapy in prostate cancer with rising prostate-specific antigen (PSA) levelsJanuary 23, 2015
A vaccine therapy designed to boost the body's immune response may join available early treatment options for prostate cancer.
Less than 20 percent of top-ranked health sites advise against screening for prostate cancer, a recommendation made by the USPSTF.
The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. This discovery is likely to help physicians to decide how closely to monitor men who are potentially at risk for prostate cancer, which is one of the most confusing and controversial dilemmas in health care.
The proportion of men with advanced-stage prostate tumors at diagnosis has dropped dramatically since the widespread implementation of PSA screening, but the proportion of men with aggressive cancers at diagnosis has not changed substantially.
The AUA developed its new clinical guideline on castration-resistant prostate cancer by creating six index patients to represent the most common clinical scenarios encountered when managing the disease.
New guidelines from the American Urological Association advise men aged 55 to 69 years who are considering prostate cancer screening to talk with their doctors about the benefits and harms of testing.
Many older men who are found to have prostate cancer after PSA screening receive treatment despite advancing age, poor health, or low-risk disease.
The American College of Physicians (ACP) recommends against prostate-specific antigen (PSA) screening for men older than age 69 and many others.
Use of biennial strategy with longer interval for low PSA levels reduces tests, false-positive results.
A recent study showed evaluating prostate-specific antigen measurements taken over time improves the accuracy of aggressive prostate cancer detection compared with a single measurement of PSA.
Physicians' practice styles related to informed decision-making for prostate-specific antigen (PSA) screening are linked to their personal beliefs about screening.
A clinic-based technique of targeted biopsy using MRI and ultrasound may improve the diagnosis and management of prostate cancer.
- Most Influential in Breast Reconstruction Decision: Surgeon, Spouse, GP
- Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma
- MOCHA App Helps Breast Cancer Survivors Achieve Weight-Loss Goals
- Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults
- SABCS: Modest Weight Loss Cuts Postmenopause Breast Cancer Risk
- Loratadine Reduced Bone Pain Associated With Breast Cancer Treatment
- Bio-individualized Diet Helps Breast Cancer Survivors Stabilize Weight, Glucose
- FDA Grants Breakthrough Therapy Designation to bb2121 for Multiple Myeloma
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Physical Examination Sufficient Work-up for Complaints of Breast Pain
- Artificial Intelligence Promising for Breast Cancer Metastases Detection
- Exercise Reduces Severity of Chemotherapy-Induced Peripheral Neuropathy
- Clinical Aspects of Foot Health and Their Influence on Quality of Life Among Breast Cancer Survivors: A Case-control Study
- SABCS: Modest Weight Loss Cuts Postmenopause Breast Cancer Risk
- Survey Reveals Opinions, Barriers Regarding Medical Marijuana Use in Children
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|